Boston Scientific (NYSE:BSX) today unveiled new results from a clinical trial of its Watchman stroke prevention device, reporting that the cardiac implant met 2 of 3 co-primary endpoints for safety and effectiveness compared with drug therapy.
American College of Cardiology Conference (ACC)
Boston Scientific to present full safety results for Watchman heart implant
Boston Scientific (NYSE:BSX) officials changed their mind about an up-coming presentation of study results regarding the company’s Watchman stroke prevention implant, deciding to present the full safety results.
Boston Scientific hesitates to release full safety results for Watchman heart implant
Officials at Boston Scientific (NYSE:BSX) announced this week that they would reveal only limited patient safety results when they present data from a clinical trial of the Watchman stroke prevention implant at the American College of Cardiology conference this week.
ACC 2011 Roundup: Acute interventions almost always appropriate
A review of half a million cases from the National Cardiovascular Data Registry finds that almost all acute percutaneous coronary interventions meet "acceptable" guidelines, but showed that only half of elective PCIs toed the line.
Neuros Medical touts pain-blocking device study | Research roundup
Neurotechnology startup Neuros Medical Inc. reported encouraging results from the first in-human study of its device that blocks pain for amputees.
The Willoughby, Ohio-based company said that four of five patients in the study reported that its device reduced their pain to “zero,” according to a statement from the company.
ACC 2011: Cordis stents equal to open heart bypass surgery
A new study, sponsored by Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. suggests that stents and bypass surgery may be equally effective in treating left main coronary artery disease.
Korean researchers at the Asan Medical Center in Seoul compared Cypher sirolimus-eluting stents made by Cordis with traditional bypass surgery in 600 patients suffering from left main coronary artery disease. The Precombat trial was funded by Cordis, the Cardiovascular Research Foundation of Seoul and a grant from the Korean Ministry of Health.
ACC 2011: Has Wall Street given up on stents?
ACC 2011: Positive Promus Element results don’t help Boston Scientific
Boston Scientific Corp. (NYSE:BSX) may have set the bar higher with its new Promus Element stent, at least according to one physician at the American College of Cardiology’s annual meeting, but Wall Street remains unmoved by the success.
Despite positive two-hear results from a five-year study of its next-generation Promus Element stent, the Natick, Mass.-based medical device maker’s stock slipped 1.2 percent yesterday and opened even lower today, at around $7.18.
ACC 2011: Drug-eluting stents can help in bypass surgeries
Drug-eluting stents can help patients who underwent open heart bypass surgery, according to new data, meaning they need fewer revascularization procedures after their surgeries.
Abiomed gains on Impella trial results
Shares of Abiomed Inc. (NSDQ:ABMD) ticked up 1.6 percent today on data showing that it helps high-risk patients during emergency heart treatment.
Data from the Protect II clinical trial of its Impella 2.5 heart pump, presented today at the annual meeting of the American College of Cardiology in New Orleans, showed that the device "provides superb hemodynamic support during high-risk interventions," according to lead investigator Dr. William O’Neill of the University of Miami.
ACC 2011: Abbott touts results of bio-resorbable stent
Abbott Laboratories (NYSE:ABT) is touting the results of a study of its bio-resorbable stent for the treatment of coronary artery disease.